Background: In the United States of America (USA), cannabis is legal in 28 states for medical purposes and 8 states for recreational use. In 2016, the legal marijuana industry reached nearly $7 billion in sales in the USA alone. Although consumption continues to increase, the medical effects of marijuana remain understudied. Young males comprise the demographic most likely to consume cannabis, and these individuals will be most vulnerable to its short-and long-term consequences. Objective: The purpose of this manuscript is to systematically review the available literature describing the effects of marijuana on male infertility, sexual health, and urologic neoplasms. Materials and methods: A comprehensive literature search was conducted using the Medline and Embase databases through May 2017. In vitro models, animal models, case series, case-control, and cohort designs were included. The Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement was utilized to report results. Results: After exclusions, 91 articles were synthesized for qualitative analysis. Of these manuscripts, 30 pertained to marijuana and male infertility, 36 discussed cannabis and male sexual health/hormones, and 25 explored the relationship between marijuana and urologic neoplasms. Discussion: With respect to male factor fertility using semen parameters as a surrogate, cannabinoids likely play an inhibitory role. Data on marijuana and male sexual function are mixed but suggest that marijuana may enhance the subjective experience of sexual intercourse while potentially contributing to ED in a dose-dependent manner. Cannabis has been associated with both increased and decreased risk of malignancy depending upon the target organ. Marijuana exposure seems to be an independent risk factor for testis cancer, data on bladder cancer are conflicting, and the evidence on prostate cancer supports anti-neoplastic effects of cannabinoids. Conclusion: Studies of the effects of cannabis suggest impact on urologic health and disease. Prospective, long-term studies are necessary for further elucidation of these effects.
INTRODUCTION
Consumption of cannabis for medical and recreational purposes is on the rise. At present, medical marijuana is legal in 28 states in the USA, and recreational use has been legalized in 8 states as well as Washington, D.C. In the USA, consumers spent an estimated $6.9 billion on legal cannabis products in 2016, up 34% from 2015. Projections suggest that this market will grow to $21.6 billion by 2021 (Abernathy, 2017) . It is estimated that 183 million individuals, comprising approximately 3% of the world population, consume marijuana (United Nations Office on Drugs and Crime, 2017) . A US government-funded survey found that approximately 22 million individuals partake in cannabis use, with 8% of individuals reporting use in the last month and 13% reporting use in the last year. Furthermore, an estimated 30% of marijuana consumers meet the criteria for a substance use disorder (Center for Behavioral Health). As a result, it is almost certain that the widespread usage of cannabis will have a profound impact on political, economic, and medical landscapes moving forward.
The active component of marijuana is D 9 -tetrahydrocannabinol (THC), an exogenous cannabinoid, which binds cannabinoid receptors located in the nervous system and reproductive organs, among many other locations (Rossato et al., 2008) . Cannabinoid receptors are members of the superfamily of seven-transmembrane-spanning receptors and are coupled to G proteins. Signaling through G proteins leads to downstream effects on calcium release, phosphorylation of intracellular messengers, and regulation of nuclear transcription factors (Howlett, 2005) . Marijuana has been shown to affect the central nervous system and has been associated with psychotic disorders and cognitive deficits (Levine et al., 2017) . Advocates of medical marijuana assert that it can effectively treat patients with a variety of serious ailments, including seizure disorders, pain, nausea and emesis, and glaucoma.
Research on the long-term effects of cannabis is in its infancy and will become increasingly relevant as medical and recreational legalization continues to expand. Given that marijuana consumers are predominantly males of reproductive age (Smith et al., 2010) , the potential effects of cannabis on male reproductive, sexual, and oncologic health are of particular contemporary significance. The purpose of this systematic review is to highlight the currently available research on the relationship between marijuana and male factor infertility, sexual health, and urologic neoplasms. Synthesis of the current data will reveal gaps in our current understanding and facilitate development of a roadmap for future investigation.
METHODS

Search strategy
A comprehensive literature search was conducted using the Medline and Embase databases through May 2017. The search was restricted to articles written in English. The following keywords and MeSH terms were utilized: 'marijuana', 'cannabis', 'cannabinoids', and 'endocannabinoids' which were then crossed with one or more of the following terms: 'infertility' (male), 'semen analysis', 'hypogonadism', 'testosterone', 'gonadotropins', 'libido', 'erectile dysfunction', 'testicular cancer', 'germ cell tumor', 'prostate cancer', 'penile cancer', 'bladder cancer', 'kidney cancer', 'renal carcinoma'. Studies included in vitro models, case series, case-control, and cohort designs. Search strategies were adapted to other databases based upon the MEDLINE parameters. We utilized the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement to report results.
Data screening and extraction
Sources were independently obtained and reviewed by two individual authors (SR and MJR) to determine eligibility based upon relevance to the effect of marijuana on men's health. First, titles and abstracts were screened for relevance. Publications went on for full-text review if they mentioned a relationship between cannabis, cannabinoids, or marijuana with one of the previously reported MeSH terms. Articles that passed the screening process were then deemed eligible for inclusion in the manuscript based on review of the full text. Publications were excluded if they did not describe studies performed human, in vitro, or mammalian species or if they were review articles. Any disagreement was resolved by the corresponding author (TJW). Figure 1 depicts the results of the systematic search.
RESULTS
The search strategy yielded seven clinical studies (Table 1) and 23 animal/in vitro studies (Table S1 ) describing the relationship between marijuana and male factor infertility. Overall, the clinical studies suggest that cannabis consumption has a negative impact on fertility using semen parameters as a surrogate. Only one of the clinical studies did not find a relationship between marijuana usage and fertility. All of the animal/in vitro studies reported a negative or potentially negative impact of cannabis on male factor fertility.
With respect to the association between marijuana and male sexual health/hormones, a total of 15 clinical studies (Table 2) and 21 animal/in vitro studies (Table S2) were identified. Overall, there did not appear to be a significant relationship between long-term cannabis consumption and the HPG axis hormones in the clinical studies, although two studies with small sample sizes did report lower testosterone and LH levels in long-term users. In terms of libido and sexual experience, nearly all the clinical studies were based on subjective questionnaires. One study found that the mean International Index of Erectile Function (IIEF) score in cannabis users was not significantly different from controls. In contrast, the animal and in vitro studies overall suggested a negative or potentially negative impact of marijuana on hormones and sexual health. Table 3 depicts the clinical studies elucidating the relationship between cannabis and urologic malignancies. Four studies were identified for testis cancer, one for prostate cancer, two for bladder cancer, and one for penile cancer. No clinical studies were identified that described an association between marijuana and renal neoplasms. Marijuana consumption appears to be an independent risk factor for the development of testicular germ cell tumors. The single clinical manuscript studying prostate cancer did not find a relationship between cannabis and prostate cancer risk; however, in vitro and animal studies overwhelmingly suggest a protective effect of cannabinoids on prostate cancer development (Table S3 ). Similarly, the few studies describing the link between marijuana and bladder cancer suggest a potentially protective effect. The single clinical study pertinent to penile cancer did not find a relationship, and the two basic science studies on kidney cancer and cannabis merely characterized the expression of cannabinoid receptors in renal neoplasms.
DISCUSSION
Cannabinoids have been shown to have biologic activity in almost all organ systems within the human body. In the central nervous system, cannabinoids have been implicated in pain, seizures, inflammation, anxiety/fear, addiction, and neurodegenerative disorders. In the cardiovascular system, hypertension, atherosclerosis, and cardiomyopathies may be partially modulated by cannabinoid activity. The gastrointestinal system, musculoskeletal system, and integumentary system also demonstrate cannabinoid activity that may contribute to regulation of disease processes including inflammatory bowel disease, osteoporosis, acne, and allergic dermatitis (Ligresti et al., 2016) . The myriad biologic effects of cannabinoids highlight potential therapeutic roles for these agents in chronic disease states. The purpose of this systematic review was to focus on the available literature describing the effects of marijuana within the male genitourinary system.
Cannabis and male factor infertility
The endogenous cannabinoid (endocannabinoid) system has been shown to function in male germ cells via the action of anandamide (AEA) and 2-arachidonoylglycerol (ADG) at 140 Andrology, 2019, 7, 139-147 cannabinoid (CB1, CB2) and vanilloid receptors (Schuel et al., 2002; Lewis et al., 2012) . A 2012 study found that seminal plasma from infertile males, regardless of exposure to marijuana, demonstrates a marked reduction of AEA and ADG in comparison with seminal plasma from fertile men. Furthermore, binding to the vanilloid receptors was undetectable in infertile spermatozoa. From this study, the authors conclude that the endocannabinoid system is altered in infertile spermatozoa, that it may play a pivotal role in capacitation and the acrosome reaction, and that these disturbances may impact fertilization outcomes (Lewis et al., 2012) . In vitro studies have also explored the effects of THC on human sperm function. This cannabinoid has a dose-dependent detrimental effect on percentage progressive motility that becomes more pronounced as overall semen quality declines. Spontaneous acrosome reactions are also reduced, and THC is able to inhibit the acrosome reaction even when it is artificially induced at both therapeutic and recreational plasma levels (Whan et al., 2006) . Spermatogenesis is a highly specialized process that is dependent upon a nurturing microenvironment created in part by Sertoli and Leydig cells in the testis. The presence of cannabinoid receptors on these cells suggests a role for cannabinoids in the balance of molecular signaling that creates this microenvironment. For example, CB2 can be found on Sertoli cells and modulation of this receptor has been shown to play a role in AEAinduced apoptosis in Sertoli cells (Maccarrone et al., 2003) . In addition, Leydig cells express the cannabinoid receptor CB1 (Gye et al., 2005) . This receptor induces a reduction of testosterone production locally, which may impact sperm development (Wenger et al., 2001) .
Clinically, seminal plasma AEA levels have been shown to be significantly lower in men with asthenozoospermia or Yes. Decrease in motility, concentration, total sperm count, and normal morphology Close et al. (1990) Case-control IV 164 No, although there was an increase in seminal leukocytes Amoako et al. (2014) Case-control IV 90 Yes. Decrease in motility and viability Lewis et al. (2012) Cohort IV 150 Yes. Reduction in endocannabinoid levels in infertile seminal plasma paralleled by increased degradation:biosynthesis ratios Amoako et al. (2013b) Cross sectional VI 86 Yes. Reduction in endocannabinoid levels in men with abnormal semen analyses Pacey et al. (2014) Case-control IV 318 Yes. Decreased normal morphology Gundersen et al. (2015) Cohort IV 1215 Yes. Decreased concentration and total sperm count NA, not applicable.
© 2019 American Society of Andrology and European Academy of Andrology Andrology, 2019, 7, 139-147 oligoasthenoteratozoospermia in comparison to men with normal semen quality, and mRNA transcripts of the cannabinoid receptor are significantly decreased (Amoako et al., 2013a,b) . Exogenous cannabinoids such as D 9 -tetrahydrocannabinol are likely to compete with endogenous cannabinoids at the cannabinoid receptors. This may alter the natural balance of this signaling system within spermatozoa with resultant effects on sperm function and fertility (Amoako et al., 2014) . A 2014 unmatched case-referent study describing modifiable and non-modifiable risk factors for poor sperm morphology, defined as <4% normal forms, found that use of cannabis in the 3 months prior to sample collection in men 30 years or less (318 cases) doubled the risk of poor morphology when adjusted for other risk factors (Pacey et al., 2014) . Limitations of this study include relatively small sample size and low participation rate. Another study from 1990 described an association between marijuana consumption and pyospermia in infertile men; however, statistical significance was not achieved after adjusting for sexually transmitted diseases and multiple substance exposures in a multivariate model (Close et al., 1990) .
A compelling clinical study was published in August 2015 that investigated the association between cannabis use and male reproductive hormones and semen quality. This study recruited 1200 Danish men age 18-28 who provided semen and blood samples, underwent a physical examination, and answered questionnaires regarding marijuana and recreational drug usage during the past three months. The authors found that routine usage of cannabis more than once per week was associated with a nearly 30% reduction in median sperm concentration and total sperm count after adjustment for confounding variables including hours of abstinence prior to providing the semen sample, tobacco and alcohol consumption, sexually transmitted diseases, and other recreational drug usage. The effect was compounded if other recreational drugs were consumed, reducing the concentration and total sperm count by more than 50% under these circumstances (Gundersen et al., 2015) . Limitations of this study include reporting bias and lack of information regarding amount of cannabis consumed and duration of abstinence.
In addition to intentionally delayed childbearing and increased rates of obesity, drugs such as marijuana are a potential contributing factor to the 15% infertility rate among couples attempting to conceive a child (Sharlip et al., 2002) .
Cannabis and male sexual health
There is a small body of literature to support the inhibitory function of the endocannabinoid system on erectile function from in vitro, animal, and human studies. While there are many factors contributing to the central neurologic control of erections, it is known that the paraventricular nucleus of the hypothalamus contains CB1 receptors and modulates erectile function and sexual behavior (Argiolas & Melis, 2004) . In animal studies, erections can be artificially induced by injecting CB1 receptor antagonists directly into the paraventricular nucleus. The proposed mechanism suggests that local antagonism of CB1 results in diminished GABA release and increased glutamate, which in turn results in increased nitric oxide production and oxytocin release (Melis et al., 2004; Castelli et al., 2007) . Oxytocin is an established contributor to sexual arousal, erections, and ejaculation (Veening et al., 2015) . Achieving an erection is dependent upon the relaxation of smooth muscle within the corpora cavernosa. While it has been determined that CB1 and CB2 receptors are present within nerve fibers of corpora cavernosa of mammalian species, including humans, endocannabinoid signaling through these receptors has demonstrated contradictory effects in different species (Gratzke et al., 2010) . For example, relaxation of erectile tissue is promoted by endocannabinoids in rats and rabbits, while signaling via endocannabinoid receptors in primate corpora cavernosa antagonizes relaxation (Ghasemi et al., 2006; Vural et al., 2009; Gratzke et al., 2010) . These in vitro studies suggest that endocannabinoids may result in diminished erectile function in primate species via local mechanisms in the erectile bodies.
Clinically, there has been conflicting data on the effect of cannabis on human male sexual function. The available data consist of subjective reports and informal questionnaires probing the experiences of cannabis users, and the dearth of studies limits our ability to draw meaningful conclusions. Some reports suggest that 70-85% of marijuana consumers experience increased sexual pleasure and satisfaction, 25-40% experience prolonged duration of intercourse, and 55-70% experience heightened sensation during orgasm (Tart, 1970; Halikas et al., 1982; Dalterio et al., 1985) . However, frequent marijuana smokers have also reported sexual dysfunction such as inhibited orgasm, premature ejaculation, and dyspareunia (Johnson et al., 2004; Smith et al., 2010) . The effect of cannabis on sexual desire and motivation may be dose-dependent, with smaller doses providing stimulation and larger doses having negative effects (Koff, 1974; Chopra & Jandu, 1976; Abel, 1981) .
In comparison with those who abstain from cannabis, daily marijuana users exhibit nearly double the rate of erectile dysfunction (Cohen, 1982) . The mechanism for erectile dysfunction in such individuals may be vascular in nature. Aversa et al. performed penile arterial duplex ultrasound with detailed penile blood flow and veno-occlusive plethysmography studies in recreational cannabis users and age-matched controls. They found that cannabis users had significantly lower penile artery peak systolic velocity as well as diminished vasodilatation in response to ischemia on veno-occlusive plethysmography, suggesting that chronic consumption of marijuana contributes to endothelial dysfunction and vascular erectile dysfunction (Aversa et al., 2008) . However, in a clinical survey of 4350 men who were screened for use of cannabis and its sexual effects, there was no identifiable link between frequent cannabis use and difficulty sustaining an erection (Smith et al., 2010) . This contradiction highlights the need for better studies to elicit the relationship between marijuana and male sexual function. Taken together, a plausible explanation for these inconsistencies is that cannabis-related sexual effects are dose-dependent with lower doses serving as a stimulus and higher doses providing a barrier to male sexual wellness. Another theory is that marijuana simultaneously enhances sexual desire and experience via altered perception but simultaneously diminishes erectile function.
Cannabis and the hypothalamic-pituitary-gonadal axis
The data regarding the relationship between cannabis and male reproductive hormones are also inconsistent. Centrally, it , 2004) . The proposed mechanism is endocannabinoid signaling via receptors in the hypothalamus inhibiting GABA release, which in turn diminishes GnRH release with consequently lower LH levels (Farkas et al., 2010) . Clinically, the mechanism of any potential relationship between cannabinoids and testosterone is unclear. The earliest studies from the 1970s found that chronic cannabis consumption significantly lowered plasma testosterone levels in a dosedependent fashion (Kolodny et al., 1974) . However, others have failed to replicate these findings (Cushman, 1975; Wall et al., 1978) . One plausible explanation for these discrepancies may be related to the temporal effect of marijuana on testosterone levels, with consumption of cannabis leading to a temporary decline in measured testosterone that is reversible. In the acute setting, several studies have shown statistically significant declines in plasma testosterone levels 30 min to 6 h after cannabis consumption (Kolodny et al., 1974; Wall et al., 1978) . When subjects smoke marijuana for a period of four weeks, one study found that testosterone levels dropped to 60% of baseline. However, after a one-week period of abstinence, testosterone level returned to 84% of baseline (Cohen, 1976) . Several other studies did not detect an effect of acute or chronic cannabis usage on plasma testosterone levels (Cone et al., 1986; Friedrich et al., 1990; Block et al., 1991) . Despite the contradictory data, no study has shown that marijuana usage, regardless of dose or duration, is associated with statistically significant decline in plasma testosterone levels outside the range of established normal values.
Cannabis and urologic cancers
Testicular germ cell tumors (TGCTs) are the most common malignancy in young men, and 84% of TGCTs occur between age 15 and 44 (McGlynn & Cook, 2009 ). The incidence of nonseminomas peaks ten years earlier (20s-30s) in comparison with seminomas (30s-40s) (Reis et al., 2007; Verhoeven et al., 2008) . Risk factors for development of TGCTs include cryptorchidism, prior diagnosis of testicular cancer in the contralateral testis, disorders of sexual development, testicular atrophy, prior testicular biopsy, hernia/hydrocele, male infertility, atopic location, family history, HIV/AIDS, age, and race (Swerdlow et al., 1987 (Swerdlow et al., , 1997 Moller et al., 1996 Moller et al., , 1998 Dieckmann & Pichlmeier, 2004; Fossa et al., 2005) . The incidence of TGCTs is on the rise for unknown reasons. Given that marijuana consumption is simultaneously increasing, there is potential for an association between cannabis and TGCTs. Several studies have explored this hypothesis.
In 2009, Daling et al. reported a population-based case-control study demonstrating that men age 18-44 with TGCTs (n = 369) were nearly double as likely to be current marijuana smokers compared with controls (n = 979, OR 1.7). When stratified by histologic subtype, the association was stronger in men with non-seminomatous and mixed histology tumors (OR 2.3). Age at first use and frequency of use appeared to modify the risk, with younger age (OR 2.8) and higher frequency of usage (OR 3.0) resulting in increased risk (Daling et al., 2009) . These findings were corroborated by case-control studies performed in 2011 and 2012, independent of other known risk factors for TSCGTs (Trabert et al., 2011; Lacson et al., 2012) . Finally, a meta-analysis of these three studies was performed in 2015. This study showed that current marijuana use increased overall risk of TGCT development by 62%, but when stratified by type of tumor (seminoma vs. non-seminoma), the effect was only sustained for NSGCTs (OR 2.09). The same results were seen in men who consumed cannabis at least weekly or for more than ten Figure 2 Current understanding of the effects of cannabis on male infertility, sexual health, hormonal health, and urologic neoplasms.
144 Andrology, 2019, 7, 139-147 years (OR 2.59 and 2.40 for NSGCTs, respectively) (Gurney et al., 2015) . The authors concluded that the biological link between cannabis exposure and testicular cancer may be related to disruption of the HPG axis. Another explanation for the increased risk of TGCTs in marijuana users could be related to the potential mutagenic and genotoxic effects of THC (Reece & Hulse, 2016) . Finally, a third plausible theory is that cannabis usage may accelerate the development of NSGCTs in men who are already genetically or environmentally predisposed rather than contributing to an overall increased lifetime risk. At this point, the overall pathway from cannabis to NSGCTs remains unclear.
There have been a select number of publications investigating the relationship between cannabis and other urologic cancers. Chacko et al. demonstrated a significant association between marijuana and transitional cell carcinoma (TCC) of the bladder in a case-control study adjusted for known risk factors including exposure to agent orange, aniline dyes, vinyl chloride, and ionizing radiation. Patients with TCC were more likely to report habitual cannabis consumption and a significantly higher quantity of consumption (Chacko et al., 2006) . However, limitations of this study included the small sample size and lack of adjustment for cigarette smoking. The role of cannabis in malignant transformation of urothelial cells may be supported by findings that THC levels in the urine have a half-life of up to 60 h in comparison with 12 h for nicotine metabolites. In addition to the carcinogens present within marijuana smoke, it has been shown that consumption transiently diminishes detrusor contractility (Kado et al., 1985; Huestis & Cone, 1998) . This may lead to delayed bladder emptying and increased duration of exposure of urothelium to toxic metabolites (Caplan & Brigham, 1990; Pertwee & Fernando, 1996; Wade et al., 2003) .
Directly opposing these findings, an in vitro experiment by Yamada et al. in 2010 suggested that cannabinoids may be protective against urothelial cell carcinoma. The authors demonstrated a dose-dependent decrease in cell viability of high-grade urothelial carcinoma cells in response to increasing concentrations of a cannabinoid receptor agonist. This was paralleled by an increase in intracellular calcium concentration and induction of apoptosis (Yamada et al., 2010) . Similarly, a large 2015 cohort study of 34,000 men reported a 45% reduction in bladder cancer incidence among cannabis users aged 45-69 users when adjusted for tobacco usage, age, race, and BMI and followed over an 11-year period. The effect was even more pronounced for men age 45-54, with a 75% reduction of incident bladder cancer in this cohort of marijuana consumers (Thomas et al., 2015) .
With respect to prostate cancer, in vitro studies have demonstrated that THC induces apoptosis in human prostate cancer cells in a dose-dependent manner (Ruiz et al., 1999) . Further support was provided by a study illustrating that administration of cannabinoid receptor agonists resulted in a dose-and timedependent inhibition of cell growth and promoted apoptosis. Blockage of CB1 and CB2 receptors on human prostate cells significantly prevented this effect. Furthermore, agonism of the cannabinoid receptors resulted in decreased secreted prostatespecific antigen levels and diminished expression of the androgen receptor (Sarfaraz et al., 2005) . Other studies have also supported the anti-neoplastic effects of cannabinoids on prostate cancer (McAllister et al., 2015; Orellana-Serradell et al., 2015) . Collectively, these data suggest that non-psychoactive cannabinoid receptor agonists could be developed as novel therapeutic agents for prostate cancer treatment.
A case-control study considering the relationship between penile cancer risk and cannabis found no significant association (Maden et al., 1993) . To our knowledge, no study has examined the relationship between marijuana and renal cell carcinoma (RCC), although cannabinoid receptors are expressed and may be downregulated in RCC (Larrinaga et al., 2010 (Larrinaga et al., , 2013 .
As more states progress toward legalization of marijuana, it is evident that further prospective studies on the impact of marijuana use on male reproductive, sexual, and oncologic health are necessary. Such studies could be conducted in states where recreational use is currently permitted. For example, one could design an experiment in which current marijuana consumers were randomly assigned to different groups and exposed to different concentrations of THC after a pre-determined washout period and assessment of baseline characteristics. Effects on semen parameters and sexual function could then be documented in a prospective fashion. Such a design would help to elucidate the THC exposure at which negative effects are seen on semen parameters and provide evidence to support or refute the hypothesis that the effects of THC on sexual function (i.e., libido, erectile function, orgasm) are dose-dependent. Cannabis research is currently in its infancy, and future studies will undoubtedly have widespread impacts on social interaction, health care, and public policy.
CONCLUSIONS
It is apparent that the current body of evidence describing the effects of cannabis on male infertility, sexual health, hormonal health, and urologic neoplasms is lacking. Figure 2 summarizes our current knowledge base. The majority of studies have been performed in in vitro and animal models, and clinical studies have not necessarily mirrored the basic science conclusions. Additionally, a large number of these investigations are outdated and anecdotal. There is a clear need for more focused, contemporary, objective studies examining the relationship between marijuana and male health, demonstrated by the number of studies with contradictory findings.
With respect to male factor fertility, it seems likely that cannabinoids play an inhibitory role. The data on cannabis and male sexual function are mixed, but overall suggest that marijuana may enhance the subjective pleasurable experience of sexual intercourse while also contributing to organic erectile dysfunction. In addition, these effects may be dose-dependent. Interestingly, cannabis has been associated with both increased and decreased risk of malignancy depending upon the target organ. While testicular cancer seems to be associated with cannabis exposure, the data on bladder cancer are conflicting, and the evidence on prostate cancer supports anti-neoplastic effects of marijuana.
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